There are currently 58 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
NCT06024499
Recruiting
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/24/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +3 locations
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Register for Updates
Systems Biology of Early Atopy
NCT04798079
Recruiting
The goal of this study is to establish a birth cohort that collects prenatal and early life biosamples and environmental samples and rigorously phenotypes young children for food allergy and Atopic Dermatitis (AD) to identify prenatal and early life markers of high risk for food allergy and AD, as well as biological pathways (endotypes) that result in these conditions. Primary Objectives: To study the role and interrelationships of established and novel clinical, environmental, biological, and... Read More
Gender:
All
Ages:
0 years and above
Trial Updated:
04/23/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +11 locations
Conditions: Allergic Diseases, Food Allergy, Atopic Dermatitis
Register for Updates
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
NCT06119529
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants. Blood tests will be performed to investigate how the body processes the LY3872386 following single and multiple dosing in healthy participants and participants with atopic dermatitis. Blood tests will also be performed to investigate how the body processes the prednisone in healt... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2024
Locations: CenExel ACT, Anaheim, California +3 locations
Conditions: Healthy, Atopic Dermatitis
Register for Updates
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
NCT04455906
Recruiting
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Gender:
All
Ages:
Between 6 years and 65 years
Trial Updated:
04/17/2024
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Atopic Dermatitis
Register for Updates
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
NCT06300697
Recruiting
This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consisting of obtaining blood and skin samples from participants at baseline. Individuals may also undergo a clinically indicated oral food challenge and have blood and skin samples collected at various time... Read More
Gender:
All
Ages:
Between 10 years and 55 years
Trial Updated:
04/10/2024
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Atopic Dermatitis, Food Allergy, Healthy
Register for Updates
Dupilumab De-escalation in Pediatric Atopic Dermatitis
NCT06116526
Recruiting
This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.
Gender:
All
Ages:
Between 1 year and 17 years
Trial Updated:
04/09/2024
Locations: Johns Hopkins Univerisity, Baltimore, Maryland
Conditions: Atopic Dermatitis
Register for Updates
Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
NCT06345404
Recruiting
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Corvus Clinical Trials Information, Burlingame, California
Conditions: Atopic Dermatitis
Register for Updates
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT04864886
Recruiting
Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal. Researchers want to learn more to better treat conditions that affect immune response. Objective: To learn about how the immune system and skin healing are related to each other. Eligibility: People ages 18-75 with primary immune deficiency, eczema, or psoriasis. Health... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
Register for Updates
Bone Health in Patients With Atopic Dermatitis
NCT03800004
Recruiting
This study examines the bone health in children with atopic dermatitis
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
03/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: Clear Dermatology & Aesthetics Center/Investigative MD, Scottsdale, Arizona +62 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839
Recruiting
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Eczema Treatment Center of New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
Register for Updates
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: First Oc Dermatology, Fountain Valley, California +29 locations
Conditions: Atopic Dermatitis
Register for Updates